{
  "doc_id": "Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση",
  "created_date": "2024",
  "country": "EL",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "3SY. KNATHRIUS H.O.C. OF THE MISSION OF THE MISSION OF THE MISSION OF THE MISSION OF THE MISSION.....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................",
      "start_page": 3,
      "end_page": 9
    },
    {
      "heading": "Covid19, a new special chapter dealing with Vaccines in oncology patients has been added,",
      "text": "of implementation, its modernization. C50.4, C50.5, C50.8, C50.8, C5.8, C5.0, C5.0, C5.0, C5.0, C5.0, C50.0, C50.0, C50.9, Ptoinna mcoaria 1k:",
      "start_page": 10,
      "end_page": 12
    },
    {
      "heading": "1. AC or EC",
      "text": "Doxorubicin 60 mg/m or Epirubici n 75-90 mg/m2, IV Cyclophosphamide 600 mg/m 2, IV",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2. TC",
      "text": "Docetaxel 75 mg/m², IV\nCyclophosphamide 600 mg/m², I V",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "3. AC or EC + Taxane",
      "text": "Doxorubicin 60 mg/m or Epirubici n 75-90 mg/m2, I Cyclophosphamide 600 mg/m2, IV Paclitaxel 80 mg/m2 IV, each week for 12 cycles DSeomceetioxsel 7 15:- 1a00 mepeg/lmeg2e tIVA, 1444434444444444444444444444444444422222222244333333333333333333333333333333333333333333333333333333333333333",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "4. FEC",
      "text": "5-FU 500 mg/m2, IV Epirubicin 75-100 mg/m2, IV Cyclophosphamide 500 mg/m2 , IV Csametheus i2ω1s: estuary in ngdia α6s kmyoksl FoEuCs for 6 cycles suggests",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "5. FEC + Taxane",
      "text": "5-FU 500 mg/m2, IV Epirubicin 75-100 mg/m2, IV Cyclophosphamide 500 mg/m2 , IV lus, or 175 m g/m m2 IV, Mr Paclitaxel 175 mg/m2 IV, every 21 days for 4 cycles or Dmoeciotaxe:l t7o5 σ-1x0h0h",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "6. TAC",
      "text": "Docetaxel 75 mg/m2, IV Doxorubicin 50 mg/m2, IV Cyclophosphamide 500 mg/m2, IV Csamethe i2h1h: er see gdioach 6ik garden chcolrocrisy muse parnotarthococcyencephalic cherno-cygae in the xygae.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Cyclophosphamide 100mg/m2, days 1 -14, PO",
      "text": "Methotrexate 40 mg/m2 , days 1.8, IV 5-FU 600 mg/m2, days 1.8, IV",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "8. CMF (intravenous)",
      "text": "Cyclophosphamide 600mg/m2, d1+8 Methotrexate 40 mg/m2 , d1+8 5-FU 600 mg/m2, d1+8",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "9. TCH (patients with HER2+ volume)",
      "text": "Docetaxel 75 mg/m2, IV Carboplatin AUC 6, IV Trastuzumab cycles 6 mg/kg, IV (after the charging dose of 8 mg/kg) Every 21 days for 6 cycles, continuation of trastuzumab as the plus 10. TCHP (comple with HER2+ volume) Docetaxel 75 mg/m2, IV Carboplatin AUC 6, IV",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "12. Paclitaxel + Trastuzumab",
      "text": "Paclitaxel 80 mg/m2 IV, each week for 12 cycles Trastuzumab 2 mg/kg, IV (after the charging dose of 4 mg/kg) each week for 12 cycles Asymolecular: prraosttueznuommeab 6 e μigl/okg, IgVia and epox 2",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "13. Neratinib",
      "text": "Sneermaetionisb 2:4 0 mg, PO, every day for 12 months for patients with HER2+ tumor who have completed one year of treatment with trastuz it is known whether it benefits patients treated with trastuzumab and pertuzumab. zumab.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "14. Pembrolizumab and Chemotherapy",
      "text": "Pembroizumab: 200 mg every 3 weeks or 400 mg every 6 weeks. During the neoadjuvant phase pembroizumab should be given in combination with chemotherapy for 24 weeks (8 doses of 200 mg every 3 weeks or 4 doses of 400 mg every 6 weeks). During the adjuvant phase of pembroizumab should be administered as α for 27 weeks (9 doses of 200 mg every 3 weeks or 5 doses of 400 mg every 6 weeks)",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "15. Olaparib",
      "text": "Olaparib 300mg twice daily, treatment duration 1 year for patients at increased risk of relapse, HER2 negative and BRCA mutations. For seropositive disease Olaparib may be co-administered with endocrine Alternatives to intravenous administration of trastuzumab may be used the subcutaneous form at a fixed dose of 600 mg (without charging dose) every 3 weeks. Alternatively to intravenous administration of the combination trastuzumab",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "A1. EPOCURATE ORMONOTHERAPY",
      "text": "The standard treatment is administration of tamoxifen (tamoxifen) 20 mg/day for 5-10 years. 16 letrozole (letrozole) 2.5 mg/day may be discussed based on the estimated risk of relapse. ovarian suppression with LHRH analogue. Supplemental administration of LHRH is recommended in patients with hormone-sensitive disease below 35 LHRH every 3 months",
      "start_page": 16,
      "end_page": 19
    },
    {
      "heading": "B. STATISTICAL DISEASE",
      "text": "overexpression/strengthening or not of HER2 (c-erbB-2) the previous treatment (if anthracycline and/or taxane have been administered as adjuvant and interval Generally in patients who have high hormone receptor expression and negative HER2 and if they have not",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "B1. HARMONIOUS DISEASE",
      "text": "Inhibition of cyclodependent kinases 4/6 [CDK4/6 synaptic dose (abemaciclib, palbociclib, ribozole, ribozole, ritrozole, citrozole, citrozole, citrozole, citrozole, citrozole, citrozole, and citrozole.",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Tamoxifen. (tamoxifen) 20 mg/day",
      "text": "Cyclodependent kinase inhibitors 4/6 [CDK4/6 (abemaciclib, palbociclib, ribociclib)] will Everolimus has been approved in combination with exemestane for the treatment of advanced breast cancer in postmenopausal HR+/ HER2-women following disease progression in non- 3. Fulvestrant 5.",
      "start_page": 20,
      "end_page": 21
    },
    {
      "heading": "Epirubicin 75-100 mg/m2, IV or doxorubicin 60-75mg/m2, IV Every 21 days",
      "text": "5. or Doxorubicin 20mg/m2, IV weekly.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "8. Vinorelbine 25-30 mg/m2, IV or 60-80 mg/m2, PO, days 1, 8 , every 21 days",
      "text": "Pegylated liposomal doxorubicin (Caelyx) 50 mg/m2, IV Liposomal doxorubicin (Myocet) 60-75 mg/m2, IV Nanoparticle-bound paclitaxel (Abraxane) 260 mg/m2, IV in 30’ infusion",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "12. Gemcitabine 800-1200mg/m2, IV D1, D8 every 21 days",
      "text": "Trastuzumab deruxtecan for HER2 IHC 1+ or 2+/ISH negative after pr",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "mg/kg IV day 1 every 21 days",
      "text": "Sacituzumab govitecan for hormone sensitive, HER-2 negative endocrine treatment with CDK4/6 inhibitor and at least 1 mg/kg D1, D8 every 21 days 2. Bevacizumab 10 mg/Kg every 14 days, IV+ Paclitaxel 90 mg/m2 week Bevacizumab 15 mg/Kg every 21 days",
      "start_page": 22,
      "end_page": 31
    },
    {
      "heading": "cancer. J Clin Oncol 2001; 19:3103.",
      "text": "76 surgery plus chemotherapy in HER2-positive Breast-Brammable Cancer Cancer, 2010: a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021 Jan;22(1):85-97. 72.Tomasz Byrski, Jacek Gronwald.",
      "start_page": 32,
      "end_page": 36
    },
    {
      "heading": "C56",
      "text": "a) Stages IA and IB in low modulation volumes (grade 3) b) Stages IC-IV CONSERVATION TREATMENT (MAINTENANCE)",
      "start_page": 37,
      "end_page": 38
    },
    {
      "heading": "I.",
      "text": "Paclitaxel 175 mg/m , IV + Carboplatin AUC-5-7, IV every 3 weeks for 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "II.",
      "text": "Paclitaxel 80 mg/m , IV every week + Carboplatin AUC 6 IV every 3 weeks for 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "III.",
      "text": "Carboplatin AUC-5-6, IV every 3 weeks for 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "IV.",
      "text": "Bevacizumab has been approved in combination with paclitaxel and carboplatin for 6 cycles of treatment, followed by maintenance therapy with Bevacizumab, for first-line treatment of patients with advanced (stage IIIB, IIIC and IV v FIGO) epithelial ovarian cancer,",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "a.",
      "text": "The recommended dose of Bevacizumab is 15 mg/kg body weight given once",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "b.",
      "text": "Treatment with Bevacizumab should be administered with caution during and at risk of bleeding. If bevacizumab is co-administered with chemotherapy to",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "V.",
      "text": "In patients with advanced (stage III and IV v. FIGO) high degree of malignancy epithelial maintenance therapy cancer with PARP inhibitors Niraparib (Zejula) and Olaparib (Lynparza). This indication of Lynparza concerns only patients who have been identified as carriers of pathogenic mutations or potentially pathogenic mutations of genital (germline) and/or somatic (somatic) cells",
      "start_page": 38,
      "end_page": 39
    },
    {
      "heading": "a.",
      "text": "The recommended starting dose of Niraparib is 200 mg (two capsules or two 100 mg film-coated tablets), taken once daily. However, for patients with a body weight of  77 kg and an initial platelet count of  150,000/μMA, the recommended starting dose is 300 mg (three capsules or three 100 mg film-coated tablets), once daily. The decision for Niraparib was based on the random data.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "VI.",
      "text": "Maintenance therapy with co-administration of Olaparib and Bevacizumab was approved, based on the results of the PAOLA-1 study, in patients who have a complete or partial response to Bevacizumab and whose cancer is associated with homologous recombination (HRD) deficiency, defined by the existence of a pathogenic or potentially pathogenic mutation in the BRCA1/2 genes and/or the dose of Olaparib is 300 mg taken daily.",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "I.",
      "text": "Platinum-based chemotherapy (Carboplatin or Cisplatin combined again with Paclitaxel or with other a. Pegylated Liposomal Doxorubicin (PLD). b. Gemcitabine. c. Topotecan.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "II.",
      "text": "The combination of Pegylated Liposomal Doxorubicin (PLD) with Trabectedin (Yondelis) (study ET743-OVA-301), indicated in platinum-sensitive recurrence (PFI > 6 months). Trabectedin is given every 3",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "III.",
      "text": "weeks as 3 hour IV injection 1.1 mg/m2, immediately after PLD 30 mg/m2. The combination of Bevacizumab with Carboplatin/Gemcitabine (OCEANS study) or Carboplatin/Paclitaxel (GOG-0213) and continuation of Bevacizumab as a post-chemotherapy treatment. The recommended dose of Bevacizumab is body",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "a.",
      "text": "The recommended daily dose of olaparib in the tablet form is 300mg (2 tablets of 150mg) 2 times a day, equivalent to a total daily dose of 600mg and can be administered to patients regardless of mutation in the BRCA1/2 genes. The decision for Olaparib was based on the data of the randomised studies Study 19 (phase II) and SOLO-2 (phase III), and SOLO-2 (phase III).",
      "start_page": 41,
      "end_page": 42
    },
    {
      "heading": "I.",
      "text": "Chemotherapy is recommended with any of the above drugs other than Cisplatin, Carboplatin. Topotecan, PLD or Epirubicin is considered as a novice.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "II.",
      "text": "The combination of Trabectedin with PLD is not indicated in platinum-resistant recurrence.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "III.",
      "text": "The combination of Bevacizumab with the above drugs (Gemcitabine, Topotecan, PLD) improves phase III AURELIA. denosumab/month, as long as there are no contraindications to their administration. Note 2: Olaparib as a treatment in patients with advanced ovarian cancer, who have received at least three treatment lines and carry genomic BRCA mutations, have received FDA approval, but have not received a single-stage BRCA mutation.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "I.",
      "text": "Cisplatin Doxorubicin Epirubicin Cyclophosphamide",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "II.",
      "text": "Docetaxel should be substituted for Paclitaxel if you are allergic to Paclitaxel or if",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "III.",
      "text": "1. 5-FU/leucovorin/oxaliplatin  bevacizumab IV. Capecitabine/oxaliplatin  bevacizumab V. sequential chemotherapy regimens. In these cases i) Irinotecan, ii) Oxaliplatin iii) Vinorelbine after detailed justification by the treating physician iv)Etoposide and v) Tamoxen patients mainly",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "VI.",
      "text": "Microspatial instability control (MSI) or immunohistochemical control of MRR proteins, the immunohistochemical expression of HER2 protein, the mutation control of the BRAF gene and the expression control of the folic acid receptor (FRa). Recently approved by the FDA a new drug that is an antibody-drug conjugate (ADC) for patients with subtropical platicular epiplating.",
      "start_page": 43,
      "end_page": 56
    },
    {
      "heading": "Megestrolacetate",
      "text": "Treatment of choice: (Megace®, 160 – 320 mg daily) 4. Everolimus/Letrozole (for endometrioid histological type only, with no formal id : The other combinations have not been shown to be as effective as Meg to be used in resistance to megace denosumab/month, since there are no contraindications to their administration. ncestatus 2 or post-vaccination",
      "start_page": 56,
      "end_page": 58
    },
    {
      "heading": "ADENOSARKOMA",
      "text": "adenic acid, which is a benign recommendation , and from mesencholystic 4.Csymbinase-free combination to Low grade endometrial stromal sarcoma. The prognosis and therapeutic approach of these patients is the same as ESS lowgrade. 1. Doxorubicin 25 mg/m2 IV (days 1-3) or Epirubicin 75 mg/m2 IV (day 1) alone",
      "start_page": 59,
      "end_page": 60
    },
    {
      "heading": "2. Other proposed combinations(all class 2B according to NCCN):",
      "text": "i. Fulvestrant\nii. Megestrolacetate\niii. Medroxyprogesteroneacetate\niv. GnRHanalogs\nMeri\nexpre\nOnco\nic-Bernstam F, Ma\nessing solid tumo\nology Annual Mee\nakker V, Oaknin A, et al. Efficacy and safety of trastuzu\nors: DESTINYPanTumor02 interim results. Presente\neting; June 2–6, 2023; Chicago, Illinois.\numab deruxtecan in patients with HER2-\ned at the American Society of Clinical",
      "start_page": 60,
      "end_page": 65
    },
    {
      "heading": "C53, C53.0, C53.1, C53.8, C53.9",
      "text": "Human papillomavirus (HPV). Inoculation, against subtypes of HPV, does not negate the current The treatment plan followed in early-stage FIGO patients (IA, IB1 and IIA 4 cm) [3] i. either radical hysterectomy (with or without adjuvant radiotherapy) ii. or radical chemoradiotherapy with Cisplatin 40 mg/m2 weekly along with radiotherapy",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "Complementary Romanic (adjuvant) chemoradiotherapy after hysterectomy",
      "text": "i. deep stromal filtration (1/3), regardless of tumor size ii. either post-infarct post-radial phabilal filtration (1/3), with volume size >2 cm iii. or surface filtration (1/3), with volume size >5 cm B. Volume size >4 cm and deep or intermediate stromal filtration (1/3) A. Positive pelvic lymph nodes [pN1 or p3]",
      "start_page": 66,
      "end_page": 68
    },
    {
      "heading": "CI, 61.8-73.0) vs. 57.3% (95% CI, 51.2-62.9) of disease-free patients at 24 months; HR 0.70 (95%)",
      "text": "CI, 1.55-0.89) P = 0.0020) [24]. The FDA has given approval for the combination, while approval from EMA is pending. Cisplatin 50 mg/m2, day 1, IV + Topotecan 0.75 mg/m2, day 1-3, IV alone with cisplatin. Although the regimen is highly myelotoxic, with appropriate support no Ifosfamide 5 g/m2.",
      "start_page": 68,
      "end_page": 69
    },
    {
      "heading": "3. Epirubicin",
      "text": "4.Cyclophosp hamide",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "5. Ifosfamide",
      "text": "6. 5-Fluouracil Paclitaxel-free survival was not officially indicated for the disease, but worldwide it is used as 1-line treatment drugs (e.g. Gemcitabine, Vinorelbine). Based on the randomised GOG-240 study it was shown that the addition of Bevacizumab to chemotherapy in the combinations Paclitaxel with platinum or Topotecan improved patient survival [17] and was approved",
      "start_page": 69,
      "end_page": 71
    },
    {
      "heading": "C34, C34.0, C34.1, C34.2, C34.3, C34.8, C34.9",
      "text": "A. MICROCULTURE CANCER Pneumonoma (MKP) covariant efficacy was demonstrated with a placebo-administered dose-free cisplatin/etopolside study of patients with no dose reduction. The combination of chemotherapy and immunotherapy with (carboplatin and etoposide for 4 cycles together with atezolizumab given as maintenance therapy to worsening of the disease)",
      "start_page": 73,
      "end_page": 76
    },
    {
      "heading": "1. Topotecan",
      "text": "1.5 mg/m2, days 1-5, IV",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "or Topotecan",
      "text": "IV 1,3 mg/m2, days 1-5, P.O. 2. CKyaclhoep 2h1o cycle approval days 1,3 mg/m2, IV + Adriamycin 45 mg/m2, IV + Vincristin 1.4 mg/m2, IV Note 2: Patients with bone metastases may receive bisphosphonates/ 3-4 weeks or, denosumab/month, Irin",
      "start_page": 76,
      "end_page": 80
    },
    {
      "heading": "B.2. COMPLETE (ADJUVANT) TREATMENT",
      "text": "patients with N1 disease, N2 [4]. Most data are derived from the combination of vinorelbine/cisplatin. Younger patients with non-component chemotherapy (substitute chemotherapy) are treated with a combination of multiplexel, gemcitabine or pemetrexed. In most analysis by the National Cancer Database showed a similar benefit for patients with a greater Complementary chemotherapy in an operable MMCP stage I-II.",
      "start_page": 80,
      "end_page": 81
    },
    {
      "heading": "Recommended treatment regimens adjuvant treatment",
      "text": "1. Cisplatin 100 mg/m2, day 1, IV + Vinorelbine 30 mg/m2, days 1, 8, 15, 22, IV Every 28 days, 4 cycles (ANITA) 2. Cisplatin 50 mg/m2, days 1, 8, IV + Vinorelbine 25 mg/m2, days 1, 8, 15, 22, IV Every 28 days, 4 cycles (JBR-10) 3. Cisplatin 100 mg/m2, days 1, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8,",
      "start_page": 81,
      "end_page": 85
    },
    {
      "heading": "B.4.1. SYSTEM CHEMOTHERAPY OF FIRST LINE",
      "text": "EFR- / ALK-/ BRAF-/ROS1-negative combination of cisplatinic quintets with PS 0-2 that do not exhibit significant comorbidity. In patients with general condition index (PS) 0-1 the choice therapy is the combination of two cytostatics that have potency and indication in the cisplatin, carboplatin, docetaxel, paclitaxel.",
      "start_page": 86,
      "end_page": 87
    },
    {
      "heading": "Vinorelbine/Cisplatin",
      "text": "Vinorelbine Cisplatin Gemcitabine/Cisplati Gemcitabine Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Docetaxel/Cisplatin",
      "text": "Docetaxel Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Pemetrexed/Cisplatin",
      "text": "Pemetrexed Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Etoposide/Cisplatin",
      "text": "Etoposide cisplatin dplat21 mg dplatin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin claptin clapt",
      "start_page": 87,
      "end_page": 89
    },
    {
      "heading": "Docetaxel/Gemcitabine",
      "text": "Docetaxel 100 mg/m2 D8, q21d Gemcitabine 1100 mg/m2 D1.8, q21d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Paclitaxel/Gemcitabine",
      "text": "Paclitaxel 200mg/m2 D1, q21d Gemcitabine 1000 mg/m2 D1,8, q21d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Paclitaxel/Vinorelbine",
      "text": "Paclitaxel 135 mg/m2 D1, q15d Vinorelbine 25 mg/m2 D1, q15d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Gemcitabine/Vinorelbine",
      "text": "1000 mg/m2 D1.8, q21d Gemcitabine 25 mg/m2 D1.8, q21d Vinorelbine",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Patients with General Status Index (PS) 2",
      "text": "Chemotherapy prolongs survival and improves the quality of life in patients with PS 2 in relation to are accepted treatment options for patients with PS2, after discussion and updating of A randomised phase III study argues that the combination of carboplatin/pemetrexed offers a significant survival benefit over pemetrexed alone as a first-line treatment in patients with a chemotherapy marker with carboplatin significantly improves survival with respect to chemotherapy in patients with PS",
      "start_page": 89,
      "end_page": 91
    },
    {
      "heading": "Bevacizumab",
      "text": "In the randomised phase III study ECOG 4599, bevacizumab improved overall survival in combination with paclitaxel/carboplatin in patients with PS 0-1 alone and may be administered to patients with non-plateletic MMCP who show no contraindications to the use of bevacizumab. The randomised AVAiL study, which examined bevacizumab in combination with gemcib",
      "start_page": 91,
      "end_page": 92
    },
    {
      "heading": "AVAiL",
      "text": "1 Cispla Gemc Bevac Day2 1 mg Day dmq2 Day; 15mgq2 mg Day dmq2; 15mgq2 dmq2 dmq2; 15mgq2 dmq2 dmq2 dmq2 dmq; 15mgq2 dmq2 dmq2 dmq2 dmq; 75gbq Point gclit Carbo bevac Point Carbo Peme Bevac 4599 taxel oplatin cizuma L atin cizuma cizuma atin cizuma dizuma atin dizuma atin dizuma atin dizuma atin dizuma atin dizuma atin dizuma atin dizuma atin dizuma atin dizuma atin dizuma atin atin dizuma atin dizuma atin r atin r atin r atin rrr",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "CHEMOTHERAPY OF CONSERVATION (MAINTENANCE)",
      "text": "(continuation maintenance. usually of non-platinum, either administration of a new chemotherapeutic/targeted agent after completion of initial chemotherapy (switch maintenance). Phase III factors showed that administration of pemetrexed and erlotinib as ‘switch maintenance' did not show a first-line chemotherapy benefit. The phase III PARAMOTUN study showed that administration of pemetrexed and erlotinib as ‘switch maintenance', offers a first-line chemotherapy benefit.",
      "start_page": 93,
      "end_page": 111
    },
    {
      "heading": "Patients with RET rearrangements",
      "text": "Adult rearrangements of the RET gene, a transmembrane protein with a significant response to tissue homeostasis at baseline. Elpercatinib, a selective inhibitor of RET (Rearranged during Transfection) was examined in the LIBRETTO-001 study in patients with RET fusions with responses reaching 64% in pre-treated measurable disease, with 23% of the",
      "start_page": 112,
      "end_page": 116
    },
    {
      "heading": "ASSOCIATIONS WITH EFR TRANSLATIONS",
      "text": "Most patients with EFR mutations show progression of the disease after approximately 913 months of treatment with erpotinib; gefitinib or afatinib; treatment of these patients depends on whether it is local therapy; osimerinib (confirmed T790M mutation) or administration of systemic incriminating T790M mutation in the exon 20 of EFR.",
      "start_page": 116,
      "end_page": 134
    },
    {
      "heading": "2) Epithelioid histological type",
      "text": "Patients with epithelials unresectable mesothelioma were advised to receive a treatment-preparation combination of 95% survival versus 16.5 months in the chemotherapy arm, a difference not statistically significant (HR=0.86) according to the results of the CHECKMATE 743 study. The mean total survival in the immunotherapy arm was 18.7 months versus 16.5 months in the chemotherapy arm, a difference not statistically significant (HR=0.86).",
      "start_page": 134,
      "end_page": 135
    },
    {
      "heading": "4) Alternative options",
      "text": "The combination of pemetrexed, cisplatin, and pembrolizumab were given an alternative treatment arm to toxicities. The greatest benefit was seen in patients with non epithelioid histology. of cisplatin/pemetrexed. PFS was similar (7.13 months in the chemo-immunotherapy arm directly compared to the combination of ipilimumab/ nivolumab. [9]",
      "start_page": 135,
      "end_page": 143
    },
    {
      "heading": "• CAP:",
      "text": "cisplatin 50 mg/m + doxorubicin 50 mg/m + cyclophospamide 500 mg/m day 1, in cycles 21 CmAePr + ω π πο ποοο: cisplatin 30 mg/m days 1-3 + doxorubicin 20 mg/m day 1-3 + cyclophosphamide 500 EmPg:/m day 1",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "Pembroizumab",
      "text": "200 mg per three weeks, only in thymic carcinoma, to disease progression, Etoepmofsiadneis:the unacceptable toxicity or maximum for 2 years. Ifosfamide :days 13 emetoside 120mg/m , every 3 weeks to 8 cycles Pemetrexed h:days 15 Ifosfamide 1.5g",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "(including LAR)  prednisone: Octreotide 0.5 mg Y.D. TID  Prednisone 0.6",
      "text": "5-FmU g+/ lkegu/cdoavino eroin: 1 year of Cimcitabine: 15 5-FU 300370mg/m + leucovorin 200mg/m per 28 days Paclitaxel: days 1, 8, 15 gemcitabine 1000mg/m every 28 days Sunitinib: days 1, 8, 15, 22, and 36,",
      "start_page": 144,
      "end_page": 170
    },
    {
      "heading": "Gemcitabine:",
      "text": "1000 mg/m2, days 1, 8, 15 , IV Capecitabine plus gemcitabine Capecitabine 830mg/m twice daily D1-D Gemcitabine1000mg/m IVdays 1, 8, 15 , IV",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "Modified FORFIRINOX",
      "text": "Oxaliplatin 85mg/m IV D1 Leucovorin 400mg/m IV D1 Irinotecan 150mg/m IV D1 Fluorouracil2,400mg/m IV in 46 hours injection D1- Gemcitabine 1000 mg/m2, each week, for 3 weeks continuous administration of 5FU (225 mg/m2 24-hour intravenous Gemcitabine (1000 mg/m2)",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "FOLFIRINOX",
      "text": "Oxaliplatin 85mg/m IV D1 Leucovorin 400mg/m IV D1 Irinotecan 180mg/m IV D1 Fluorouracilc 400mg/m IV D1 IV bolus Fluorouracil 2,400mg/m IV in 46 hours injection D1-D2",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "Modified FOLFIRINOX",
      "text": "Oxaliplatin 85mg/m IV D1 Leucovorin 400mg/m IV D1 Irinotecan 150mg/m IV D1 Fluorouracil 2,400mg/m IV in 46 hours injection D1-D2 Gemcitabine plus nab-paclitaxel Gemcitabine: 1000 mg/m2, days 1, 8, 15 , IV Nab-paclitamg",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "NALIRIFOX",
      "text": "Liposomal Irinotecan 50 mg/m2 Oxaliplatin 60 mg/m2 Leucovorin 400 mg/m2 5-FU 2.400 mg/m2 This regimen was examined in the Napoli 3 study and showed statistically significant and clinical benefits in total survival and progression-free survival of the disease (FDA approved & EMA submitted).",
      "start_page": 179,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine",
      "text": "1000mg/m2, days 1, 8, 15, IV, after \"charging\" with 7 consecutive weeks of treatment",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine 1000mg/m2, IV + Cisplatin 50mg/m2, days 1, 15, IV",
      "text": "with BRCA 12 or PALB2mutations",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine",
      "text": "Erlotinib 1000mg/m2, days 1, 8, 15, IV, after prior \"charge\" with 7 consecutive weeks of treatment and 1 week stop + (Tarceva) 100 mg daily continuously, PO",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Liposomal Irinotecan 70 mg/m intravenously over 90 minutes, followed by Leucovorin",
      "text": "400 mg/m intravenously over 30 minutes, followed by 5-FU 2,400 mg/m intravenously on fluorouracil (5-FU) and leucovorine (LV), in adult patients who have progressed after oxaliplatin or irinotecan (FOLFOX, FOLFIRI, OFF)",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Σχήμα OFF",
      "text": "IVucovorin (200 mg/m ) recommended by 5-FU (2,000 mg/m2 in 24 hour continuous infusion on days 1, 8, 15, and 22 and oxaliplatin (85 mg/m on days 8 and 22) treatment alternatives for patients with MMR deficiency-MSI Pembrolizumab 200mg IV, 1 day (85 mg/m on days 8 and 22).",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "For patients with NTRK fusion",
      "text": "Larotrectinib 100mg daily 2 times a day (EMA & FDA approved) Entrectinib 600mg once a day (EMA & FDA approved) For patients with BRAF V600E mutations there are satisfactory alternative treatment options. (Under FDA accelerated approval) Dabrafenib + Trametinib Dabrafenib 150mg PO twice daily Trametinib 2 mg PO once daily For patients",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "For patients with germline BRCA 1/2 mutations",
      "text": "IV-based chemotherapy without worsening the disease (EMA & FDA-approved) Olaparib 300 mg regimen of PO twice daily as maintenance therapy denosumab/month. Oxaliplatin Should be administered without specific justification under the FOLFIRINOX or GemOx regimen. in NCCN guidelines (17). FOLFIRINOX led to an increase in survival.",
      "start_page": 182,
      "end_page": 190
    },
    {
      "heading": "For patients with high TMB (Tumor Mutational Burden)",
      "text": "Pembrolizumab 200mg, day 1, IV Pembrolizumab 400 mg, day 1, IV For patients with high TMB (Tumor Mutual Burden, TMB limit 10 mut/ by NGS platform FoundationOne CDx assay (or by other valid pl treatment options (FDA approved).",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "For patients with NTRK fusion",
      "text": "Larotrectinib 100mg 2 times a day (FDA & EMA approved) Entrectinib 600mg once a day (EMA & FDA approved) pero, for 14 days, PO rated approval) /Mb), such as this ad",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "For patients with FGFR2 fusion",
      "text": "Pemigatinib alone is indicated for the treatment of adults with locally advanced or growth factor 2 (FGFR2) that has progressed after at least one previous line The recommended dose is 13.5 mg Pemigatinib taken once daily for 14 days, with an interval of 7 days out of treatment. (FDA & EMA approved). Futibatinib alone with Futibatinib is indicated for treatment",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "Ivosidenib alone is indicated for the treatment of adult patients with locally advanced",
      "text": "metastatic cholangiocarcinoma with an IDH1 R132 mutation, which were pre-supplied",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "The recommended dose is 500 mg Ivosidenib (2 x 250 mg tablets) taken orally once daily.",
      "text": "by the patient. ( FDA &, EMA approved ) For patients with BRAF V600E mutations Dabrafenib + Trametinib there are satisfactory alternative treatment options. (Under FDA accelerated approach) Dabrafenib 150mg PO twice daily Trametinib 2 mg PO once daily",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "For patients with RET fusions",
      "text": "Selpercatinib satisfactory alternative treatment options. (Under FDA accelerated approv If SB  50 kg: 120 mg PO twice daily If SB >50 kg: 160 mg PO twice daily The combination of Gemcitabine/ Cisplatin has given survival advantage to random denosumab/months, since there are no contraindications to their administration as well. val viruses) of the hepatitis type",
      "start_page": 192,
      "end_page": 197
    },
    {
      "heading": "local control of the disease etc. In the systemic treatment arm the administration of Sorafenib to patients with",
      "text": "good general condition (0-2 against ECOG) and Child-Pugh score A has been shown to improve survival of ICD-10 Diagnosis:",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "Sorafenib",
      "text": "Sorafenib 400 mg morning and 400 mg evening daily",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "Lenvatinib",
      "text": "60 kg: 8 mg PO daily 60 kg: 12 mg PO daily",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Atezolizumab plus bevacizumab",
      "text": "Atezolizumab 1200 mg BKaevthaec 2iz1u μmaebre 15 mg/kg αTrethmeneolinm kuami satbo syfsn. durvalumab Durvalumab in combination with Tremelimumab indicated HIMALAYA. Durvalumab 1,500 mg administered in combination with Tre D1/ durvalumab",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Regorafenib",
      "text": "160mg PO D1-D21",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Cabozantinib",
      "text": "60 mg PO",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Ramucirimab",
      "text": "8mg/kg IV in patients with aFP400 ng/ml IMbrave 150 offered a benefit of surviving emelimumab 300 mg as a single dose of f",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Nivo umab ipilimumab",
      "text": "Combination of 1mg/kg and 3mg/kg every 3 weeks for 4 doses followed by administration of 240 mg of Novolumab every 2 weeks (FDA approval) nivolumab as alone or in combination with ipilimumab is indicated for adult patients with hepatocellular carcinoma who received sorafenib at a previous treatment line. The indication has been approved by the FDA as accelerated approval based on the overall rate and duration of apne",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "For patients with NTRK fusion",
      "text": "Larotrectinib 100mg 2 times a day (EMA & FDA approved) Entrectinib 600mg once a day (EMA & FDA approved)",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "For patients with RET fusions",
      "text": "satisfactory alternative treatment options. (Under FDA accelerated approval) Selpercatinib If SB  50 kg: 120 mg PO twice daily If SB >50 kg: 160 mg PO twice daily Doxorubicin 60mg/m2, day 1, IV Every 21 days",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "GEMOX",
      "text": "Gemcitabine 1000mg/m2, day 1, IV + Oxaliplatin 100mg/m2, day 1, IV",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "FOLFOX",
      "text": "Oxaliplatin 85mg/m D1 Leucovorin 400mg/m D1 5FU benefit 400 mg IV bolus D1 5 FU 2400mg/m2 in continuous infusion 48 hours of denosumab/month.Note 2: Regarding immunotherapy, Tremelimumab, an anti-CTLA4 inhibitor, recently received \"orphan drug design\".",
      "start_page": 200,
      "end_page": 207
    },
    {
      "heading": "Chemotherapy with FOLFOX or CAPTEM: mainly in tumors with Ki 67>15%",
      "text": "C25, C25.0, C25.1, C25.2, C25.3, C25.3, C25.7, C25.8, C25.9 Somatostatin analogues for cases of G1, G2, good and moderate streptozocin 500mg/m IV/d + 5FU 400mg/m IV/d for 5 days every 6 weeks Capecitabine (750 mg/m2 twice daily, 150 mg/m2)",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "FOLFOX",
      "text": "Epanolimus 10 mg P.O. daily car Sunipinib 37.5 mg P.O. serenomics Cplatinic Cplatinic Cplatinic Cplatinic Cplatinic Cplatinics 2.16 mg Cplatinics Cplatinic Cplatinics Cplatinics .34.2, C34.8, C37 Everolimus 10mg/day Somatin receptor G1, mid G2 mg/m m2 once C34, C34.2, C34.2, C34.2, C34.2, C34.2, C34.2, C34.2, C34.2, C3 C3 C3 C3.2, C3 C3.2, C3.3, C3 C3 C3 C3 C3.",
      "start_page": 207,
      "end_page": 213
    },
    {
      "heading": "FLOX",
      "text": "IValiplatin 85 mg/m , day 1, 15, 29, IV + Leucovorin 500 mg/ + 5FU 500 mg/m , day 1, 8, 15, 22, 29, 36 IV bolus Mayo Clinic Regimen 5FU bolus 425 mg/m , day 1-5 + Leucovorin 20 mg/m , day 1",
      "start_page": 213,
      "end_page": 218
    },
    {
      "heading": "We amend no FOLFIRI",
      "text": "Iritotecan 180 mg/m , day 1, IV + Leucovorin 400 mg/m , day 1, in a two-hour IV fortification, followed by a 5FU 400 mg/m , day 1, IV bolus and then 5FU 2400 mg/m in IV fortification",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFIRI",
      "text": "Irinotecan 180 mg/m , day 1, IV + Leucovorin 200 mg/m , days 1, 2, in a two-hour IV tinnitus, followed by 5FU 400 mg/m , days 1, 2, bolus IV and then 5FU 600 mg/m (day 1.2)",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFOXIRI",
      "text": "Irinotecan 150-165 mg/m , wed 1, IV + Oxaliplatin 85 mg/m , wed 1, IV + Leucovorin 200 mg/m , wed 1, in 2-hour IV chyme, followed by 5FU 2400-3200 mg/m in IV chyme 48 hrs",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFIRINOX ACCORD",
      "text": "Irinotecan 200 mg/m , day 1, IV + Oxaliplatin 85 mg/m , day 1, IV + Leucovorin 200 mg/m , day 1, in 2 hour IV chyme, followed by 5FU 400 mg/m , day 1, IV bolus and follow 5FU 2400 mg/m in IV .",
      "start_page": 218,
      "end_page": 222
    },
    {
      "heading": "1. Bevacizumab:",
      "text": "5  10 mg/kg and  2 weeks see  7.5 or 15 mg/kg and  3 weeks see",
      "start_page": 222,
      "end_page": 222
    },
    {
      "heading": "2. Aflibercept",
      "text": "4mg/kg in IV contusion and δ 2 weeks see in combination with δ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ μ",
      "start_page": 222,
      "end_page": 239
    },
    {
      "heading": "C61",
      "text": "1,600,000 cases and 366,000 deaths per year. Precautionary control by PSA measurement that PSA's baseline radiative rate is monitored, PSA's baseline radiative rate is confirmed, PSA's baseline radiative rate is monitored, PSA's baseline radiative rate is monitored at a localized stage often leads to the detection of patients with PSA alone (biochemical recurrence). Such relapses in general (PET-PSMA) are that of the American Urological Society (AAAAA) guidelines.",
      "start_page": 241,
      "end_page": 243
    },
    {
      "heading": "i)",
      "text": "Abiraterone acetate, 1000mg/day pre-food combined with prednisone 5mg once a patient who has at least 2 of the 3 following characteristics: Gleason score 8, presence",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "ii)",
      "text": "Apalutamide 240mg/day for both patients with high and low disease load",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "iii)",
      "text": "Enzalutamide 160mg/day for both patients with high and low disease load",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "i)",
      "text": "Chemotherapy with dositaxel (75 mg/m2 every 3 weeks) for 6 cycles with concurrent administration of abiraterone acetate 1000mg daily pre-food and prednisone 5mg twice daily to disease progression. Treatment is based on the results of the PEACE-1 study, whose analysis (ADT+Dositaxel+Abiraterone) in patients with high disease load.",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "ii)",
      "text": "Chemotherapy with dositaxel (75 mg/m2 every 3 weeks) for 6 cycles (prednisone administration is at the discretion of the attending physician) plus darolutamide 600 mg twice daily to ARASENS study. 3. Chemotherapy with dositaxel (75 mg/m2 every 3 weeks) for 6 cycles. After the results of the studies PEACE-1 and ARASENS are announced",
      "start_page": 244,
      "end_page": 258
    },
    {
      "heading": "Megatherapy (HDCT)",
      "text": "Over 3 days over 3 days of Mobilizing: VeIP x 1 HD, (Coboplatin 2100mg/m & Etoposide 2250mg/m ) x 2 INDINA UNIVERSITY ac over 3 days of Mobilizing: TI x 2 HD: ( Carboplatin AUC=24 & Etoposide 1200mg/m )",
      "start_page": 258,
      "end_page": 260
    },
    {
      "heading": "C64",
      "text": "Genetic syndromes (Von Hippel-Lindau disease, Birt-Hogg-Dubé's parietal impairment (Cycorticoid-Cycorticoid-Cycorticoid-Cyortic-Cyortic-Cyortic-Cyortic-Cyortic-Cyortic-Cyorbic-Cyortic-Cyorbital-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-Cyral-",
      "start_page": 263,
      "end_page": 269
    },
    {
      "heading": "B3. DOSOLOGY – HOW SYSTEMICAL TREATMENT WORKS",
      "text": "1. Sunitinib 50 mg/day, po, for 4 weeks followed by 2 weeks discontinuation 2. Pazopanib 800 mg, daily, continuously, PO 3. Sorafenib 400 mg, 2 times daily, continuously, PO 4. Bevacizumab 10 mg/kg, IV, every 2 weeks + Interferon-a 9 MU, YD, three weekly 5. Temsirolimus 25 mg, IV, weekly",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "6. Everolimus 10 mg/day, PO",
      "text": "7. Lenvatinib 18 mg + Everolimus 5 mg daily, per os. 8. Aximbib 5 mg, 2 times daily PO (substituted upward over dose 9. E rlotinib 150 mg/day, PO 10. Nivolumab 240mg every 2 weeks over 30 minutes or 480mg every 4 weeks 11. Nivolumab 3mg/kg + Ipilim",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "14. Cabozantinib 60mg/day - PO",
      "text": "15. Pembroizumab + Axitinib, 200 mg every 3 weeks, IV and Axitiinb 5 mg from 16. Pembroizumab 200 mg every 3 weeks, or 400 mg every 6 weeks, IV and Lenvatin Belzutifan 120 mg once daily regardless of food (3x 40mg tablets) mab, continues nib 20 mg once Note 1: In Europe, there is no approval for the combination of avelumab + axib",
      "start_page": 270,
      "end_page": 271
    },
    {
      "heading": "B 4. ESSENTIAL OBJECTION",
      "text": "In patients with bone metastases and creatinine clearance of > 30 mL min, the administration of zolendronic acid-relaxed climactic acid (4 mg/3-4 weeks) or denosumab (a RANK ligand inhibitor) (120 mg sq patient automatically as poor risk. Small studies with the combination of doxorubicin & gemcitabine or such patients are recommended.",
      "start_page": 271,
      "end_page": 279
    },
    {
      "heading": "2. Complete, \"aggressive\" TURBT",
      "text": "3. Cisplatin 20mg/m2 (days 1-5 .22-26 IV) concurrently with radiotherapy. Alternately Cisplatin 40mg/m2/week concurrently with radiotherapy. Retest with cystoscopy after 2-3 4. Cisplatin 100 mg/m2 (days 1.22 IV) concurrently with radiotherapy 1.8 Gy/day, up to a total dose of 40 Gy. Cys",
      "start_page": 279,
      "end_page": 279
    },
    {
      "heading": "Cisplatin + Gemcitabine",
      "text": "Cisplatin 70 mg/m2 (day 1) IV + Gemcitabine 1000 mg/m2 (day 1, 8), IV Dosek-daethnes 2e2 M hVmAerCe for 4 cycles Methotrexate 30 mg/m2 (day 1) IV + Vinblastine 3 mg/m2 (day 1) IV + Doxorubicin 30 mg/m2",
      "start_page": 280,
      "end_page": 282
    },
    {
      "heading": "1. Cisplatin + Gemcitabine",
      "text": "Cisplatin 70 mg/m2 (day 1) IV + Gemcitabine 1000 mg/m2 (days 1, 8), IV",
      "start_page": 282,
      "end_page": 282
    },
    {
      "heading": "2. Carboplatin + Gemcitabine",
      "text": "Carboplatin AUC 4.5-5 (day 1) IV + Gemcitabine 1000 mg/m2 (days 1, 8), IV 3. Dose-dense MVAC a. Methotrexate 30 mg/m2 (day 1) IV + Vinblastine 3 mg/m2 (day 1) IV + Doxorubicin 30 mg/m2 (day 1) IV + Cisplatin 70 mg/m2 G1",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "4. MVAC",
      "text": "a. Methotrexate 30 mg/m2 (days 1, 15, 22), IV + Vinblastine 3 mg/m2 (days 1, 15, 22), IV + Doxorubicin 30 mg/m2 (day 2), IV + Cisplatin 70 mg/m2 (day 2), IV b. Every 28 days",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "5. Cisplatin",
      "text": "70 mg/m2 (day 2) IV + Gemcitabine 1000 mg/m2 (days 1, 8, 15), IV",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "6. Enfortumab Vedotin/Pembrolizumab*",
      "text": "Enfortumab vedotin 1.25mg/Kg (days 1.8 up to disease progression) + pembrolizumab 200mg day 1 up to",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "7. Nivolumab/Gemcitabine/ Cisplatin *",
      "text": "Nivolumab 360 mg (day 1 ) + Gemcitabine 1000 mg/m2 (days 1.8 ) + Cisplatin 70 mg/m2 (day 1) every 21 days for 6 cycles and then Nivolumab 480 mg every 28 days up to 2 years The above treatment regimens have FDA approval, but not EMA (3/2024). II. ANOTHERAPE 1st line in patients unsuitable for cplatis.",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "Pembroizumab 200mg every 21 days, day 1, IV or 400 mg IV day 1, every 42 days with",
      "text": "CPS 10III. Maintenance INSURANCE after 1st line chemotherapy",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Avelumab 800mg IV every 14 days",
      "text": "Galsky et al. :ECOG PS 2, Creatinine clearance 60ml/min, significant peripheral neuropathy or hearing disorder, heart failure NYHA III. Patients who are eligible for cisplatin and have a high PDL1 expression should receive cisplatin-based chemotherapy rather than immunotherapy.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "The administration of 1st-line immunotherapy, either with Atezolizumab or Pembrolizumab in patients with",
      "text": "high PDL1 expression should be preferred in patients who do not accept any chemotherapy. unfit for cisplatin administration. In addition, there is a restriction of EMA approval only in patients with positive PDL1 expression. Atezolizumab requires PD-L1 expression  5% in tumor-filtration immune cells (IC). PD-L1 expression was evaluated with VENTANA PD2)",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Maintenance treatment with Avelumab after first-line chemotherapy demonstrated significant",
      "text": "survival advantage over optimal supportive treatment and is now considered the standard of care.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Avelumab maintenance is the preferred option even for patients with high expression",
      "text": "PDL1 that are unsuitable for cisplatin and received carboplatin-based chemotherapy.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Atezolizumab",
      "text": "Nivolumab",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "Atezolizumab 1200mg every 21 days IV",
      "text": "Pembroizumab Nivolizumab 240mg every 14 days IV or 480mg IV every 28 days Pembroizumab 200mg clinical benefit was shown in 21 days, day 1, IV or 400 mg IV day 1, every 42 days All of the above immunotherapeutic drugs have been approved by the FDA and EMA for No PDL1 expression control is required for administration of immunotherapy with the above drugs for The initial approval of Atezolozumab was based on the results",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "IV. CHEMOTHERAPY after platinum-based chemotherapy failure",
      "text": "Vinflunine 280-320 mg/m2 IV every 21 days Vinflunine has shown activity as a 2nd-line treatment in metastatic urothelial cancer and is administered at the dose of 280-320 mg/m2 IV every 21 days. After special justification other drugs such as Paclitaxel and Docetaxel may be administered.",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "1. Enfortumab Vedotin",
      "text": "Enfortumab Vedotin 1.25mg/Kg IV(days 1, 8, 15) every 28 days",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "2. Erdafitinib",
      "text": "tb Erdafitinib 8mg/day",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "3. Sacituzumab Govitecan",
      "text": "Sacituzumab Govitecan 10mg/Kg (days 1.8), every 21 days Enfortumab vedofit, a conjugate of an antibody-drug (ADFRC) against the Nectin-4 adhesion molecule and a microtubule inhibitor was approved based on the results of the phase III EV-301 clinical study that showed a benefit of overall survival against chemotherapy and immunotherapy with an PD1 inhibitor",
      "start_page": 286,
      "end_page": 287
    },
    {
      "heading": "C43, C43.0, C43.1, C43.2, C43.3, C43.4, C43.5, C43.6, C43.7, C43.8, C43.9",
      "text": "E1n. and Ipixilism. Lately administered as an adjunctive dose of effusion IIb, IIc, or III (according to AJCC) at a dose of 10mg/kgx4 doses every 3 weeks and then booster doses every 3 months to 32 .e tn,i vso lausmthaenb effusion at stage III with filtration >1 mm",
      "start_page": 290,
      "end_page": 290
    },
    {
      "heading": "4. Dabrafenib+trametinib",
      "text": "The FDA approved on 5/18 the administration of the combination to BRAF+ fully excluded stage III melanoma and with at least filtration of >1 mm into lymph node-guard at 150mgx2 +2mg/day respectively and for disease and lymph node cleansing, within 12 weeks ] [there is approval and EMA] 1st line BRAF wild-type",
      "start_page": 291,
      "end_page": 291
    },
    {
      "heading": "1. Ipilimumab",
      "text": "2. Nivolumab 3mg/kgiv every 3 weeks (4 cycles) 240mg per 2 weeks or 480mg per 4 weeks or 3mg/kg per 2 weeks or 6mg/kg per 4 weeks 3. Roeems μbr oalpizoudmektb 2 t0xmikgo tequitha 3rd with dpoemra 4.",
      "start_page": 291,
      "end_page": 291
    },
    {
      "heading": "1. Ipilimumab 3mg/kgivevery 3 weeks (4 cycles)",
      "text": "2. On choking the combination at 1 line, the phase II (LEAP-004) study of filtravavir patients at a total of 2 mg per day at 2 mg per 3 weeks plus lenvantinib 20 mg/d showed that 21.4% of patients 1st/2nd line BRAF positive disease Immunotherapy can be administered according to BRAFwild-type standards at 1st or 2nd line or at the target",
      "start_page": 291,
      "end_page": 292
    },
    {
      "heading": "DTIC",
      "text": "a. 250 mg/m2/day iv for 5 days or b. 1000 mg/m2/day 1 every 21 days c. 800mg/m2 every 15 days Temozolomide 200 mg/m2/day po for 5 days every 28 days Interleukin-2 (high doses) 720,000 IU/Kg, iv every 8 hours, times 14 shots. Recurred in mid-Protocolles",
      "start_page": 293,
      "end_page": 293
    },
    {
      "heading": ": Cisplatin 80 mg/m2, vinblastine 8 mg/m2, DTIC 800mg/m2 iv every 21 days.",
      "text": "Vindesine 2.5 mg/m2 day 1, IV",
      "start_page": 293,
      "end_page": 293
    },
    {
      "heading": "DTIC 300 mg/m2 days 1-3, IV every 21 days",
      "text": "Paclitaxel 175mg/ m2+CarboplatinAUC 5-6 IV Note 1: For the administration of TKIs to the immunization vaccinate vaccinate + vaccinate vaccinate vaccinate vaccinate + vaccinate patients in the vaccinate vaccinate + vaccinate vaccinate vaccinate to the vaccinate and in the presence of the vaccinate patients.",
      "start_page": 293,
      "end_page": 294
    },
    {
      "heading": "3. Paclitaxel",
      "text": "4. TPeemgyolzaotelodmInidtee rferon α-2b FA6.ManeKoAa dEjNuvTaOnSt aNoDsEioXIXIH     .",
      "start_page": 294,
      "end_page": 294
    },
    {
      "heading": "1. Nivolumab+relatlimab",
      "text": "2. T-VEC 31. R. Dummer, A. Hauschild, M. Guggenheim. . Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. AnnOncol (2010) 21 (suppl 5): v194-v197.",
      "start_page": 294,
      "end_page": 297
    },
    {
      "heading": "A. PLACIDES SKIN CANCER",
      "text": "The squamous carcinoma of the skin (cutaneoussquamouscellcarcinoma, CSCC) is one of the most commonly treated immunodeficiency-promised cancers of the skin. 70% - 90% of CSCC cases occur in the head and neck [1-3]. The risk of developing CSCC increases with age in both sexes, with a mean range of between 70 and 78 years [4-7]. Also, men have an increased risk of developing CSCCCs.",
      "start_page": 302,
      "end_page": 303
    },
    {
      "heading": "A. TREATMENT OF PROGRESSED (TOWNLY PROGRESSED AND metastatic) DISEASE",
      "text": "Indications: Stages II with > 2 risk factors, III and IV (according to AJCC/UICC) 1. Cemiplimab of 350mg iv may not be administered with [PROTECTED THERAPY] 2. On contraindication of treatment with checkpoint inhibitor or as a second line of systemic therapy after failure of cemiplimab of indication: Carboplatin + paclitaxel ux",
      "start_page": 303,
      "end_page": 308
    },
    {
      "heading": "A. TREATMENT OF PROGRESSED (TOWNLY PROGRESSED AND metastatic) DISEASE",
      "text": "VismodegibPO 150mg daily for patients with symptomatic metastatic basal cell carcinoma SonidegibPO 200mg daily for patients with locally advanced basal cell carcinoma (BCC) Cemiplimab 350mg iv every 3 weeks for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) in adult patients who have developed dysphoresis of the disease.",
      "start_page": 308,
      "end_page": 308
    },
    {
      "heading": "11. Summary of Product Characteristics (cemiplimab).",
      "text": "Merkel's carcinoma [MCC] is a rare malignant neuroendocrine neoplasia of the skin [1] Merkel's carcinoma anti-malignant cell carcinoma has a very high mortality rate that exceeds that of melanoma. Five-year MCC-specific survival rates range between 41%-77% depending on the PRIVATE THERAPY iv avelumab 10mg/Kg q 2 weeks [27-32]",
      "start_page": 310,
      "end_page": 316
    },
    {
      "heading": "1. Doxorubicin",
      "text": "Ifosfamide 25 mg/m2 IV (days 1-3) or Epirubicin 75 mg/m2 IV (day 1) alone or with and with 3gr/m2/H IV (days 1-3), along with Mesna at a dose of 60%- 100% of ifosfamide 2. Tyrsabtetentetadi nsupport with G-CSF regimen.",
      "start_page": 316,
      "end_page": 316
    },
    {
      "heading": "3. Doxorubicin",
      "text": "Dacarbazine 70 mg/m2 IV (day 1) and 400 mg/m IV (day-to-day defibrillator IV armopinoma IV) patients were given a special benefit in the drug ifosfamide. Support with G-CSF is recommended. The regimen is repeated 4. Dkaotheo 2ru1b imceinres. Trabectedin 60 mg/m2 IV and 1.1 mg/m IV by maintenance.",
      "start_page": 316,
      "end_page": 317
    },
    {
      "heading": "1. Gemcitabine 900 mg/m2 IV (days 1, 8) with or without",
      "text": "Docetaxel 80-100 mg/m2 IV (day 8) Recommended support with G-CSF on days 9-15 in combination. 2. Cyclophosphamide 500 mg/m2 IV (day 1) and Vincristine 1.5 mg/m2 IV (maximum dose 2 mg), (days 1 and 5) and Doxorubicin 50 mg/m2 IV (day 1)",
      "start_page": 317,
      "end_page": 322
    },
    {
      "heading": "Regorafenib,160mg 3 weeks on/ one week off, imatinib sunitinib.",
      "text": "4. Ripretinob after failure at and 5. Cabozantin, 1ib50 mg pre-inhibitors with imatinib or regorafenib. 6. , 60 mg daily as 4 line of treatment (out of indication) DrugCaAv",
      "start_page": 322,
      "end_page": 342
    },
    {
      "heading": "VDCA/IE",
      "text": "Vinceristine 2 mg/m2 (up to maximum 2 mg), day 1, IV Doxorubicin 75 mg/m2, day 1, IV Cyclophosphamide (+mesna) 1200 mg/m2, day 1, IV Actinomycin-D 1.25 mg/m2, day 1 (up to maximum 2.5 mg) Ifosfamide (+mesna) 1800 mg/m2, days 1-5, IVtopside",
      "start_page": 342,
      "end_page": 342
    },
    {
      "heading": "B. STATISTICAL DISEASE",
      "text": "In relapsed or metastatic Ewing's disease regimen: first-line chemotherapy, recent dose1t VelDA n a is what showed the fewest responses. Vinceristine 1.5 mg/m2 (up to a maximum of 2mg), day 1, IV + Doxorubicin 75 mg/m2, day 1, IV Cyclophospamide (+na) 1200 mg/m2 (up to a maximum of 2 mg), day 1, IV + Doxorubicin 75 mg/m2.",
      "start_page": 343,
      "end_page": 348
    },
    {
      "heading": "Grade Volumes 1",
      "text": "The grade I tumors are circumscribed, non-tissued ligands of IDH are not bounded by an ID1 ligand; the ligands are not bounded by a ligand; the ligands of IDH are not bounded by a ligand; the ligands of ligands are bound to a ligand; the ligands of ligands are bound to a ligand; the ligands of ligands are ligands are ligands of ligands; the ligands are ligands are ligands of ligands of ligands.",
      "start_page": 349,
      "end_page": 350
    },
    {
      "heading": "- PCV:",
      "text": "CCNU (lomustine) 90 (cycle 1) - 110 (from cycle 2) ptride is administered at a time when the total dose of molamide is increased by molamide molamine (from cycle 2) mg/m2 PO d1 mg/m2 PO d8-21 Vincristine 1.4mg/m2 (max 2mg) IV d8+29 CTH in short regimens (e.g. 2.6 Gy over 15 sessions) (17) (19). PCV (as above as above) if not administered earlier)",
      "start_page": 351,
      "end_page": 352
    },
    {
      "heading": "ASTROCYTOMA IDH – mutant grade 3 (previously called anaplastic astrocytoma)",
      "text": "at least the taking of a biopsy. Then CMR is recommended. Use at the same time as CMR Temozolomide claudication is mainly recommended in clinical treatment (75 mg/m2/day PO for 6-7 weeks continuously with CMR 2Gy/day for 5 days/week for 6-7 weeks as 60 Gy) was studied in the CATHON study and does not add benefit(24). After the end of CMR syndrome",
      "start_page": 352,
      "end_page": 352
    },
    {
      "heading": "ASTROCYTOMA IDH – mutant WHO grade 4",
      "text": "This entity with the oldest classification was described as IDH-mutant glioblastoma. It also now includes IDH – mutant astrocytomas with CDKN2A/b elimination. Patient management with this tumor can be done either as an IDH-mutant WHO grade 3 or as an IDH wild type glioblastoma below (bleed).",
      "start_page": 352,
      "end_page": 352
    },
    {
      "heading": "LANGUAGE IDH – wild type WHO grade 4",
      "text": "The term concerns the previously known as primary (IDH wild type) glioblastoma and also now all IDH wild type astrocytoma patients with necrosis and/ or microvascular proliferation are treated with molecular markers of aggressive behaviour (EGFR enhancement, TERT instigator mutation and cytogenetic longer and hypermaximal resection (supramaximal safe resection).",
      "start_page": 352,
      "end_page": 355
    },
    {
      "heading": "3. Lomustine 75 mg/m d1",
      "text": "Every 6 weeks as maximum 8 cycles 1. vincristine 1.5 mg/m max 2 mg) d1, 8, 15 2. Cisplatin 70-75 mg/m d1 3. Cyclophosphamide 1000 mg/m d 21.22 Every 6 weeks as maximum 8 cycles In 2 line of interest is the activity of the inhibitors of the path Sonic Hedgehog drastically",
      "start_page": 355,
      "end_page": 364
    },
    {
      "heading": "1. PF+ pembrolizumab:",
      "text": "(in patients with PDL1 CPS expression1) Pembroizumab 200 mg and Cisplatin 100 mg/m2 or Carboplatin AUC 5, day 1, IV and 5-FU 1000 mg/m2, days 1-5 in IV continuous infusion (6 cycles followed by maintenance with pembroizumab until unacceptable toxicity or a maximum of 24 months).",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "2. Pembroizumab:",
      "text": "(in patients with PDL1 CPS expression1) Pembroizumab 200 mg every 21 days (up to unacceptable toxicity or a maximum of 24 months).",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "3. PF + Cetuximab [EXTREME figure]:",
      "text": "(in patients with PDL1 expression CPS1) Cisplatin 100 mg/m or Carboplatin AUC 5 day 1, IV and 5-FU 1000 mg/m , days 1-4 in IV continuous Cetuximab infusion on days 1, 8, and 15 (IV 400 mg/m2, day 1 for cycle 1 and then 250 mg/m2 each (6 cycles and then maintenance with cetuximab until unacceptable toxicity or disease)",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "4. TPEX (alternatives of EXTREME scheme)",
      "text": "Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, day 1 and Cetuximab on days 1.8, and 15 (IV 400 mg/m2, day 1 for cycle 1 and following",
      "start_page": 364,
      "end_page": 365
    },
    {
      "heading": "5. TP",
      "text": "IVplatin 75 mg/m2, day 1, IV and Docetaxel 75 mg/m2, day 1, IV 6. CP Cisplatin 75-100 mg/m , IV and Paclitaxel 175 mg/m , IV Carboplatin AUC5, IV, day 1 and 5-FU 1000 mg/m , days 1-5 in IV continuous injection Cetuximab 400 mg/m IV (charge), then",
      "start_page": 365,
      "end_page": 365
    },
    {
      "heading": "1. Nivolumab 240 mg regardless of PD-L1 expression",
      "text": "have not taken immunotherapy on the 1 line or those who have taken EXTREME on the 1 line) 2. Pembroizumab 200 mg in patients with PD-L1 TPS expression50%",
      "start_page": 366,
      "end_page": 366
    },
    {
      "heading": "4. Docetaxel 75 mg/m2, IV",
      "text": "IV. Methotrexate 40 mg/m weekly, IV (3 ovations equivalent to one day cycle) 6. Docetaxel 75 mg/m , IV every 21 days and Cetuximab 400 mg/m IV (charge), and then 1 Cetuximab 250 mg/m , per week every 21 days or Cetuximab 500 mg/m every 14 days Docetaxel 75 mg/m2.",
      "start_page": 366,
      "end_page": 367
    },
    {
      "heading": "patients with PDL1 TPS expression 50%. nivolumab is administered independently of PDL1.",
      "text": "MTX is usually administered as a rescue therapy or in patients with low PS or in patients with Carbobidine-pestine approval; chemotherapy alone may not have a lower radiological effect than Cisplatin. However, it can be used together with radiotherapy interchangeably in patients with Cisplatin contrain. There are protocols e.g.: Cisplatin/5-FU, Cisplatin/Paclitaxel, 5-FU/Hdry etc.",
      "start_page": 367,
      "end_page": 379
    },
    {
      "heading": "V. MYELOEIDIS CARKINOS THIREODIES",
      "text": "is a manifestation of inherited syndromes, such as MEN 2A, MEN 2B and familial myeloid progression. Infrequently treated with a combination of acetaminophen and acetaminophen. Acetaminophen is recommended for the treatment of acetaminophen. Acetaminophen metabolomics may be present in the presence of acetaminophen. In addition, specific mutations of the RET gene appear to be associated with the prognosis and resistance of both sepercatiniibibib and other therapeutic agents.",
      "start_page": 380,
      "end_page": 384
    },
    {
      "heading": "III) DIAGNOSTIC APPROACH",
      "text": "imaging screening of the thorax and upper and lower ventricles (CTs or MRIs). Depending on the individual clinical trial the screening with PET/CT although described in retrospective studies is related to finding PET/CT Therefore the key role of PET/CT concerns specific clinical ‘scenarios' and mainly the investigation",
      "start_page": 390,
      "end_page": 390
    },
    {
      "heading": "IV) CONFERENCE",
      "text": "2. Women with metastasis in armpits LNs based on breast cancer guidelines st.H. In case of course there are 3. Men with vegetative or sclerosing bone metastases and increased PSA in the blood or positive for PSA staining in the biopic material guidelines for the prostate metastatic Ca. The same is true for men with uncommon PSA in the blood or positive PSA staining in the prostate.",
      "start_page": 391,
      "end_page": 394
    },
    {
      "heading": "2. Poorly differentiated neuroendocrine neoplasms (G3).",
      "text": "Screening of chest and upper and lower ventricles (CT/MRI) FDG-PET in the administration of chemotherapy with Cisplatin and Etoposide.",
      "start_page": 394,
      "end_page": 394
    },
    {
      "heading": "E. CHEMIOTHErapeutic schemata cape",
      "text": "1) Carboplatin AUC5, d1, IV + Paclitaxel 175mg/m , IV, d1 (Q21) x 8 cycles 2) Carboplatin AUC5, d1, IV + Docetaxel 75mg/m , IV, d21) x 8 cycles 394 3) Cispla 4) Gemc 6) Oxalip 1200mg 7)",
      "start_page": 394,
      "end_page": 425
    },
    {
      "heading": "Patient characteristic Risk",
      "text": "Site of cancer Very high risk (stomach, pancreas) 2 High risk (lung, lymphoma, gynaecological, bladder, testicular, renal) 1 Pre-chemotherapy platet count 350,000 /microL 1 Haemoglobin concentration 10 g/dl or use of erythropoies",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "0 Low 0.8% 0.3%",
      "text": "1.2 Intermediate 1.8% 2%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "3 or higher High 7.1% 6.7%",
      "text": "S t VTE > 1500 mg/m2 mg/m2 Epirubicin 90mg doxorubicin60m Actinomycin D Carboplatin AUC4 Methotrexate >50 mg/250 mg/m2 g/m2, mg/m2 /m2 – >200 m Nab-pa mg/m 2 g/m2 Na mg g/m2",
      "start_page": 425,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "125 mg at 150 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "180 mg 300 mg/0.5 mg",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO;",
      "text": "2 mg 1 mg or 0.01 mg/kg IV; 1 transdermal patch; 10 mg",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "8 mg ; 8 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "0.5 mg ; 0.25 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "100 mg once",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "5 mg ; 5 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO ή",
      "text": "α. 20 mg IV\nβ. 12 mg εάν\n80 mg oral daily on days 2 and",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "(80 mg PO daily on",
      "text": "V\nmg per os or IV καθημερινά τις",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "(30 to 90%)",
      "text": "(10 to 30%) Olanzapine 5 to 10 mg 5 to 10 mg on days 2 to 4.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "Dexamethasone 12 mg or IV (8 mg per 8 mg per os or IV on days 2",
      "text": "os if we use up to 3.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "Dexamethasone 12 mg or IV (8 mg per",
      "text": "os if we use",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "5-HT3 antagonist (one of the following):",
      "text": "μ (mu) of opioids with peripheral action. naloxegol, minimally penetrates the blood-brain barrier of Opioid constipation (opiaid-induced syndrome, OIC) in adult patients who have had inadequate and safety, which has been demonstrated in the Kodiac clinical program, [10-11] as well as in oncology patients through the pan-European study NACASY [12] and other studies [",
      "start_page": 432,
      "end_page": 433
    },
    {
      "heading": "1. Opioids.",
      "text": "The regulation of cancer pain, is done on the basis of the analgesic scale of WHO. The 5 principles of the dose should be given on the basis of the WHO scale, for mild pain (intensity from 0-3) is administered non-opioid analgesics, in terms of codeine, has an analgesic effect when metabolized into morphine, mainly through the CYP2D6. in particular, it is an antagonist of Mu receptors and at the same time inhibits its reuptake.",
      "start_page": 435,
      "end_page": 438
    },
    {
      "heading": "Paroxysmal Cancer Pain (BTcP)",
      "text": "indicated for the treatment of paroxysmal cancer pain (BTcP) in adult patients with (Abstral) pain receptors, are found to be 100-133 μg, with an upward titration, if necessary, from the range of Fetanyl nasal spray (PecFent), is designed for application to the mucosa of the nasal cannabinoid, mainly THC (tetrahydrocannabinol) and",
      "start_page": 438,
      "end_page": 447
    },
    {
      "heading": "Grade 1 Mild:",
      "text": "Rash covering 10% BSA with or without symptoms (e.g. itching, feeling",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Grade 2 Moderate:",
      "text": "Rash covering 10-30% BSA with or without symptoms (e.g. itching, feeling Rash covering >30% BSA without or with mild symptomatology",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Grade 3 Serious:",
      "text": "Rash covering >30% BSA with severe symptomatology. Restriction of Grade 4 Potentially life-threatening reactions (Grade 5 Death Indicated immediate intervention of SPF at least 30 minutes to 1 hour before sun exposure. Strong or very strong topical corticosteroids (e.g. betamethasone propionate 0.05%, triamcinolone 0.1% or clobeta",
      "start_page": 449,
      "end_page": 467
    },
    {
      "heading": "Entrectinib 600mg, once a day, continuously",
      "text": "TMB (Tumor Mutational Burden, TMB limit 10 mut/Mb), as this is determined by the NGS platform Foundation 2 CDx assay (or other valid platforms as well) and have no other treatment options, the immunotherapeutic agent Pembrolizumab has received FDA approval. Pembrolizumab 200mg total dose, day 1, IV, every 21 days or Pembrolizumab",
      "start_page": 467,
      "end_page": 468
    },
    {
      "heading": "NTRK Gene Fusion",
      "text": "Larotrectinib – C49 (NTRK gene fusion) take Sepe ercati inib total daily dose of at least 16 mg per day as an adjunctive dose of at least 12 mg per day at least after the Palliative Care is defined by the World Health Organization (WHO, 2014) as \"the approach that deficiency lege artis Mild- moderate: GFR 30-89ml/min - Depending on the opioid, dose reduction or Caution!",
      "start_page": 468,
      "end_page": 480
    },
    {
      "heading": "Confrontation",
      "text": "Dexamethasone 8-16 mg. As long as there is no improvement after 5-7 days or undesirables o Pharmacodelic Acidyl thermide, it is contraindicated to complete blockage of the intestine. Stopping in case of occurrence o Cyclozine o Haloperidol o Levomeprom - Hyoscine butylbr Morphine sulpha romide of ate (send nnabis, acotic)",
      "start_page": 480,
      "end_page": 504
    },
    {
      "heading": "HiB/ Influenza Hemophilus vaccination",
      "text": "Haemophilus influenzae is an adulterous adulterous adultererous adultererous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adultererated adulterererated adulterated adulterated adulterated adulterererererererererererated adulterated adultererererated adulterated adulterated adultererererererererererer",
      "start_page": 505,
      "end_page": 507
    },
    {
      "heading": "HPV/Human papillomavirus",
      "text": "There remains both the incidence and severity of HPV infection in this patient population.",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "HZV/ shingles vaccine",
      "text": "Emphasis                                                              .",
      "start_page": 509,
      "end_page": 512
    },
    {
      "heading": "The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is",
      "text": "",
      "start_page": 513,
      "end_page": 519
    },
    {
      "heading": "table under heading Covid19, a new special chapter dealing with Vaccines in oncology patients has been added,> (from previous page)",
      "text": "Row 1: Definition of molecular Molecular Hypotype (corresponding) Rheumatic subtypes Clinically-pathological expression Row 2: Luminal A-likeEstrogen receptor expression (ER), no hyperexpression HER2 High expression of progesteronic receptor (PR) Low Ki-67 Or Molecular signature with result compatible with low risk Row 3: Luminal B-like expression or hyperexpression",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table under heading 1. AC or EC>",
      "text": "Row 1: HER2-positive (non luminal)Yperexpression HER2 Without expression ER and PR Row 2: ‘Basal-like’NO expression ER and PR and without overexpression HER2.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading 1. AC or EC>",
      "text": "Row 1: Systemic therapy π Hypotype of rheumatic breast cancer Recommended treatment Row 2: Luminal A-likeHormonotherapy for most cases Row 3: Luminal B-likeChemotherapy in case of T3-4 tumors and/or 4 infiltrated lymph nodes. Chemotherapy followed by hormone therapy for most Row 4: Luminal B-like",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading 1. AC or EC> (column 1)",
      "text": "Row 1: HER2-positive (non luminal) Row 2: ‘Basal-like’",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading 1. AC or EC> (column 1)",
      "text": "Row 1: Systemic treatment π Subtype Row 2: Luminal A-like Row 3: Luminal B-like Row 4: Luminal B-like HER2-positive Row 5: HER2-positive (non luminal) Row 6: ‘Basal-like’",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading cancer. J Clin Oncol 2001; 19:3103.> (from previous page)",
      "text": "Row 1: Breast Cancer. N Engl J Med. 2016; 375(18): 1738-1748 Row 2: Row 3: Sikov, WM, Berry, DA, Perou, CM, et al. Impact of the addition of carboplatin and/or bevacizumab to Row 4: neoadjuvant once-per-week paclitaxel",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table under heading Etotoside/Cisplatin>",
      "text": "Row 1: Vinorelbine/Cisplatin Vinorelbine25mg/m2D1, 8, q21d D1, Row 2: Cisplatin Gemcitabine/Cisplatin Gemcitabine80 mg/ m2 1250 mg/ m2q21d D1, 8, q21d D1, Row 3: Cisplatin Docex/Cisplatin Gemcitabine80 mg/ m2 1250 mg/ m2 1250 mg/m2q21d D2q21d D22q21d D1222D1D13233333333443333333333333333433333333333333333333333333333333333333333333333",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etotoside/Cisplatin>",
      "text": "Row 1: Etoposide/Cisplatin Etoposide100 mg/ m2D1-3, q21d D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etotoside/Cisplatin> (column 2)",
      "text": "Row 1: 25mg/m2D1, 8, q21d D1, Row 2: 80 mg/m2 1250 mg/m2q21d D1, 8, q21d D1, Row 3: 75/mg/m2 75 mg/m2q21d D1, q21d D1, Row 4: 75 mg/m2 500 mg/m2q21d D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etotoside/Cisplatin> (column 2)",
      "text": "Row 1: 100 mg/ m2D1-3, q21d D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etoposide/Cisplatin> (from previous page)",
      "text": "Row 1: Docetaxel/Carboplatin Docetaxel75 mg/ m2D1, q21d Row 2: Carbopatin Paclitaxel/Carboplatin PaclitaxelAUC 6 200mg/m2D1, q21d D1, q21d Row 3: Carboplatin Pemetrexed/Carboplatin Pemetrexed",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "table under heading Patients with General Status Index (PS) 2>",
      "text": "Row 1: Docetaxel/Gemcitamine Docetaxel100 mg/ m2D8, q21d Row 2: Gemcitabine Paclitaxel/Gemcitabine Paclitaxel1100 mg/ m2 200mg/m2D1,8, q21d D1, q21d Row 3: Gemcitabine Paclitabine",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "table under heading AVAiL>",
      "text": "Row 1: ECOG 4599 Row 2: Paclitaxel Carboplatin Bevacizumab200mg/m2 AUC 6 15mgkgDay 1;q21d Day 1;q21d Row 3: AVAiL Row 4: Cisplatin Gemcibine Bevacizumab80mg/m2 1250",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "table under heading CHEMETHERAPY MAINTENANCE> (from previous page)",
      "text": "Row 1: Pemetrexed500 mg/m2, d1, q21dIn patients who did not show progression of the disease after 4 cycles of first-line CHTH with platinum Row 2: Erlotinib150 mg/daycombination. In patients with activatory EGFR mutations and stable disease after 4 cycles of CHTH with platinum",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "table under heading CHEMETHERAPY MAINTENANCE> (from previous page)",
      "text": "Row 1: Erlotinib150 mg/dayFrom oral, continuously until disease progression or non-Row occurrence: Gefitinib250 mg/dayacceptable toxicity Oral, continuously until disease progression or non-Row 3: Afatinib40 mg/dayacceptable toxicity Oral, continuously until disease progression or non-Row 4:com",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "table under heading CHEMETHERAPY MAINTENANCE> (from previous page, column 2)",
      "text": "Row 1: Erlotinib Row 2: Gefitinib Row 3: Afatinib Row 4: Dacomitinib Row 5: Osimerinib Row 6: Erlotinib Ramucirumab Row 7: Erlotinib bevacizumab",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "table under heading C64>",
      "text": "Row 1:  Row 2: Table 1. Criteria for Memorial Sloan - Kettering Cancer Centre Row 3: Lost of one criteria, correlated with good prognosis Row 4: Presence of one or two criteria, correlated with intermediate prognosis Row 5: Presence of three or more criteria, correlated with poor prognosis Row 6: (Presence of more criteria)",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "table under heading C64> (from previous page)",
      "text": "Row 1:  Row 2: Table 2 International Metastatic RCC Database Consortium (Heng Criteria) Row 3: Lost of these criteria, correlated with good prognosis Row 4: Presence of one or two criteria, correlated with intermediate prognosis Row 5: Presence of three or more criteria, correlated with poor prognosis Row 6:",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: Harbors an EML4-ALK Rearrangement and Responses to Crizotinib. Case Rep Oncol 2014; 37:628 Row 2: 33. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: Row 3: Aphasoulis E.",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 1)",
      "text": "Row 1: Harb Row 2: 33. Bria Row 3: A ph Row 4: 34. Grec Row 5: treat Row 6: 35. Grec Row 7: plus Row 8: 36. Gros Row 9: unnn Row 10: 37. Poue Row 11: carc Row 12: 38. Cass Row 13: com Row 14: plus Row 8: 36.",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 2)",
      "text": "Row 1: bors an EML4-ALK Exploration and Responses to Crizotinib. Case Rep Oncol 2014; 7:628 Row 2: asoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: Row 3: hase II Hellenic Cooperative Occidental Occidental Occidental Occidental Occidental Occidental Occidental occidental Occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental occidental",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: \nRow 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus\nRow 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "2009 1: review of 56 cases. Cancer 1987; 59:572. Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficiency of a combination of docetaxel and cisplatin with Row 4: patients with unknown primary cancer. Am Jlin Oncol. 2010:3332",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "9 Row 2: 58. Hicks RJ. Uses of molecular identified agents for the diagnosis, stigma and therapy of neuroendocrine Row 3: malaria. Cancer Imaging 2010; 10 Spec no A:S83 Row 4: 59. Strosberg JR, Coppola DS, Klimstra DS, Klimstra",
      "start_page": 401,
      "end_page": 401
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: Parameter consideredMechanics used Row 2: FunctionalityActionals of Daily Living (ADL): Instrumental Activities of Daily Living (IADL) Row 3: Accompanying Diseases‘Timed Up and Go’ test Charlson Score Index (CSI) Row 4: Mental StatusCumulative Illness Rating ScaleGtricG",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: CategoryParameters of PGAHealing Approach Row 2: Group 1: \"Capacity\" (\"fit\")No ADL and IADL dependence Without serious comorbiditiesOriginal treatment similar to younger Row patients 3: Group 2: \"Vulnerable\" (\"Vulnerable\")Absence of IADL geriatric syndrome but not ADL dependence",
      "start_page": 404,
      "end_page": 404
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: Table 1. Examples of chemotherapeutic regimens at risk E.O., 20% Row 2:  Row 4: Cancer bladder Cyst(dd)MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) Row 5: Breast cancer",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 1)",
      "text": "20 Row 1: Table 1. P Row 2:  Row 3: Cancer ur Row 4: Cancer mas Row 5:  Row 6:  Row 7:  Row 8:  Row 9: Cancer bone Row 10:  Row 11:  Row 12:  Row 13:  Row 14:  Cancer parch",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 2)",
      "text": "Forty-four: Row: Fourteen Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row, Row, Row, Row, Row: Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 3)",
      "text": "42: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 26: Row 21: Row 21: Row 22: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23 Row 23 Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 4)",
      "text": "40 Row 1: peep χ Row 2: Row 3: Row 4: Row 5: husk Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 19: Row 21: Row 22: Row 23: Row 24: Row 24: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 5)",
      "text": "40 Row 1: heaps Row 2: Row 3: Row 4: Row 5: s Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 19: Row 21: Row 22: Row 23: Row 24: Row 24: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 6)",
      "text": "42: 40: 40: 50 Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row, Row: Row: Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 7)",
      "text": "48 Row 1: raps Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 21: Row 22: Row 23: Row 24: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 8)",
      "text": "Row 1: of schematics at risk E.O. >20% Row 2:  Row 3:  Row 4: (dd)MVAC (methotrexate, vinplastine, d cisplatin) Row 5: TAC (docetaxel, doxorubicin, cyclophosp Row 6:  Row 7:  Row 7:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 9)",
      "text": "37 Row 1: % Row 2: Row 3: Row 4: doxoru Row 5: phami Row 6: Row 7: hospha Row 8: Row 9: Row 10: ab) Row 11: Row 12: ycin, Row 13: Row 14: nomyc Row 15: famide Row 17: Row 17: Row 18: my, Row 19: Row 19: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 10)",
      "text": "Row 27: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 21: Row 22: Row 22: Row 22: Row 22: Row 21: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 23: Row 22: Row 22: Row 22: Row 13: Row 13: Row 13: Row 13: Row 13: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 14: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row 11: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 11)",
      "text": "Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 22: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 13: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row: Row: Row: Row 13: Row 13: Row: Row: Row: Row: Row: Row 13: Row 13: Row 13: Row 13: Row 13: Row: Row: Row 13: Row 13: Row 13: Row 13: Row 13: Row: Row: Row 13: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMETHERAPIC CHEES CAPE> (from previous page, column 12)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1:  Row 2:  Row 3: DT-PACE (dexamethasone, thalidomide, Row 4: Multiple myelomaciaplstin, doxorubicin, cyclophosphamide, etoposide )  bortezomib (VTD-PACE) Row 5: Non-small cell lung cancer",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 1)",
      "text": "Row 1:  Row 2:  Row 3: DT-PACE (dexamethasone, thalamido Row 4: Multiple myelomaciaplstin, doxorubicin, cyclophosph borezomib (VTD-PACE) Row 5: Non-small cell lung cancerDP (docetaxel, carplatin)",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: omide, Row 4: hamide, etoposide )  Row 5: Row 6: Row 7: Row 8: Row 9: mide, etoposide) Row 10: Row 11: icin, etoposide) Row 12: Row 13: atin) Row 14: in)",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading <3 or higher High 7.1% 6.7%>",
      "text": "Row 1: Patient characteristicLisk Row 2:  Row 3: Site of cancer Row 4: Very high risk (stomach, pancreas)2 Row 5: High risk (lung, lymphoma, gynaecological, bladder, testicular, preliminary)1 Row 6: Pre-chemotherapeutic pellet",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading <3 or higher High 7.1% 6.7%>",
      "text": "Row 1: Total ScoreRisk CategoryDerivation cohort VTEValidation cohort VTE Row 2:  Row 3: 0Low0.8%0.3% Row 4: 1,2Intermediate1.8%2%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (column 1)",
      "text": "Row 1: Patient characteristic Row 2: Row 3: Site of cancer Row 4: Very high risk (stomach, pancreas) Row 5: High risk (lung, lymphoma, gynaecological, bladder, testicular, renal) Row 6: Pre-chemotherapeutic platet count 350,000 / lymphoma / gynaecological",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (column 1)",
      "text": "Row 1: Total ScoreRisk CategoryDerivation cohort VTE Row 2:  Row 3: 0Low0.8% Row 4: 1,2Intermediate1.8%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (from previous page)",
      "text": "Row 1: Emetogenic activityEndorubicin Rhabidocrimodin Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhaboxicin Rhaboxicin Rhabvir Rhabvir Rhabvir Rhabvir Rhabvir Rhabvir Rhab",
      "start_page": 428,
      "end_page": 428
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (from previous page)",
      "text": "Row 1: Breduximab bedotinRustuzumab emtansineTisotumab ventotin Row 2: PanitumabPertuzumab",
      "start_page": 429,
      "end_page": 429
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (from previous page, column 1)",
      "text": "Row 1: Breduximab vedotinRustuzumab emtansine Row 2: PanitumumabPertuzumab",
      "start_page": 429,
      "end_page": 429
    },
    {
      "heading": "table under heading (80 mg PO daily at>",
      "text": "Row 1 :  Row 2 :   Row:   Row:  Row:   Row:   Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row: Row: Row:  Row: Row: Row: Row: Row:  Row: Row: Row: Row:  Row: Row: Row:  Row:  Row: Row: Row:  Row: Row: Row: Row:  Row: Row: Row:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at>",
      "text": "Row 1: Increased risk Row 2: vomiting Row 3:(>90%) Row 4:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at>",
      "text": "Row 1: PO or Row 2: a. 20 mg IV Row 3: Row 4: b. 12 mg if Row 5: we use Row 6: unpretentious/ fosaprepitant/",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 1)",
      "text": "Row 1:  Row 2: Ki Row 3:  Row 4:  Row 5: Increase vomiting>90%Increased Row 6: indirect Row 7: (>90% Row 8:  Row 9:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 2)",
      "text": "Row 1: Row 2: Row 3: danger Row 4: Row 5: Row 6: Row 7: a Mr Row 8: s Row 9: %) Row 10: Row 11: Row 12:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 3)",
      "text": "Row 1: Row 2: Row 3: The Eme Row 4: Row 5: Row 6: Row 7: Risk Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 4)",
      "text": "Row 1: Row 2: Row 3: you Row 4: Row 5: Row 6: Row 7: nos Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 5)",
      "text": "37 Row 1:  Row 2: Farm Row 3:  Row 4:  Row 5: NK1R instead Row 6:  Row 7:  Row 8: Indecent Row 9:  Row 10:  Row 11:  Row 12:  Row 13: Indecent",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 6)",
      "text": "45 Row 1: Row 2: Row 3: acoon Row 4: Row 5: Row 6: Row 7: Tag Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Itty Row 17: Row 18: Row 19: Row 21: Row 22: Row 23: Row 23: Row 23: Row",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 7)",
      "text": "20  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row: Row: Row: Row: Row: Row, Row, Row:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 8)",
      "text": "30  Row 3:  Row 3:  Row 4:  Row 5: a:  Row 7:  Row 8:  Row 9:  Row 10: 80 mg oral daily on days 2 and  Row 11: 3.  Row 12:  Row 8:  Row 8:  Row 10:  Row 10: 80 mg oral daily on days 2 and  Row 11: 3.",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "12 Row 1:  Row 2:  Row 3: Olanzapine5 to 10 mg5 to 10 mg on days 2 to 4. Row 4:  Row 5: Moderate risk of vomiting (30 to 90%) without-carboplatin5-HT3 antagonist (one of the following):  Row 6:  Row 7:  Row 8:  Row 9:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Moderate risk of vomiting Row 2: (30 to 90%) Row 3: no-carboplatin",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: PO Row 2: Row 3: 12 mg or IV (8 mg per os if using",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Row 2: 8 mg per os or IV on days 2",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Moderate risk of vomiting Row 2: (30 to 90%) Row 3: with carboplatin",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Small risk of vomiting Row 2: (10 to 30%)",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 antagonist (one of the following):> (column 1)",
      "text": "13:  Row 2:  Row 3:  Row 4: Medium risk (30 to 90%) no-carbohydrateMedium risk Row 5: (30 to 90%) Row 6: No-carbohydrate Row 7:  Row 8:  Row 9: Medium risk (30 to 90%) with-carbohydrateMetrios",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 antagonist (one of the following):> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Hypnotic nemesis Row 5: Row 6: oplatin Row 7: Row 8: Row 9: Row 10: Hypnotic nemesis Row 11: Row 12: atin Row 13: Row 14: Row 15: Row 16: Hypnotic nemesis Row 17: Row 18:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 antagonist (one of the following):> (column 3)",
      "text": "12 Row 1:  Row 2:  Row 3: Olanzapine5 to 10 mg5 to 10 mg on days 2 to 4. Row 4:  Row 5: h5-HT3 antagonist (one of the next):  Row 6:  Row 8:  Row 9:  Row 10:  Row 11:  As on the next",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading Grade 3 Serious:>",
      "text": "Row 1: Grade 1 Mild: Rash covering 10% BSA with or without symptoms (e.g. itching, feeling Row 2: Grade 2burn, pain) Moderate: Rash covering 10-30% BSA with or without symptoms (e.g. itching, feeling hot, pain), limits daily activities Rash covering >30% BSA without or with mild symptoms",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "table under heading Grade 3 Serious:>",
      "text": "Row 1: Row 2: General measures to support and monitor skin care, which may Row 3: prevent or minimize the severity of the rash associated with administration",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Row 2: Use of loose, soft clothing and soft, comfortable shoes. Placement of gel bottoms. Row 3: Avoid long walks or intense exercise as well as applying large pressures and",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: SPF at least 30 minutes to 1 hour before exposure to the sun. Row 2: Avoid local medicines applied to treat the acne Row 3: (e.g. benzene peroxide).",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Dermal Derm toxicityaCtlicinic tcoax iHkaotriatkat chelation disease or haematopathkar a pneaTreatment Row 2: Alopecia- Result of direct toxicity of CHT in rapidly multiplying hair follicle cells. The overall incidence of alopecia after chemotherapy administration is estimated at 65%",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: more cytotoxic drugs. Inflammation of the parietal sinuses (inflammation of the sinuses) Inflammation of the sinuses (inflammation of the sinuses) is usually classified by the loss of hairs 1 to 2 months after the start of treatment.  Repeated chemotherapy cycles lead to total alopecia.  It probably reduces the duration of alopecia. Row 2:",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Row 2:",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page, column 4)",
      "text": "Row 1: more cytotoxic drugs. - Inflammation usually occurs 7-10 days after the onset of the treatment. - Abdominal sinuses Tinnitus: No loss of hair becomes more evident 1 to 2 months after the onset of treatment - Repeated chemotherapy cycles lead to total alopecia. Row 2: - Alopecia is reversible. - Escape of the drug from the vessels to the surrounding tissues. - Frequency of occurrence 0.1 – 6%, most common in children.",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: - Vlennogenitis, esophagitis, pneumonitis, if these parietal lesions were most common - parietal lesions - parietal lesions - parietal palpitations - palpitations - palpitations - palpitations in the palms and soles - It is common DAE after administration of Docetaxel, Capecitabine, 5-FU - Prodromal symptoms of dysesthesia - feeling of ny in the palms and soles are observed.",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Skin agents, treat Toxicity/ Pharmaceutical agentsClinical Characteristics H.Treatment Row 2: AEGcmFroe iindhei beixtaonrths MEC verbs inhibitorsIt is usually localized on the head and upper thoraxThoracic vultures and pustules, without pecs, usually localized on the head and upper thorax",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: - Isotretinoin 10-20 mg in case of Row 2: XegarFofluorinous effluents virulence fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants fulminants .",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page, column 4)",
      "text": "Row 1: - Isotretinoin 10-20 mg in case Row 2: non-responsiveness to tetracyclins Dizziness parietal rashes - Moisturizing preparations without aromas - Local corticoids in case of eczema of lesions. Row 3: Grade 1 - Local application of antibiotics and antiseptics (chlorhexidine, potassium permanganate, iodide povidone, chlorin solution)",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: MKIs- Systemic corticoids (prednisone Row 2: LCDeuKk4th/ 6 inhibitors- White spots, asymptomatic - May be localized at0.5-1 mg/kg qd to resolution of rash - Monitoring - Local corticoids - Cream pimecrolims-tacrolims",
      "start_page": 456,
      "end_page": 456
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Dermal Toxicity/ Pharmaceutical FactorsClinical TreatmentsPolical Abdominal PulsionsPulsative PulsantsPulsative Cortisosis Strongly TreatedRow 2: Cilidoblastic use C1Bl1 Row 4: rashes Eczematic-type reactionsSee C2Erythematomatic plaques with mild exfoliationLocation mainly at the extremitiesAccomes",
      "start_page": 457,
      "end_page": 457
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page, column 4)",
      "text": "Row 1: Clinical Characteristics Row 2: Row 3: See C1 Row 4: See C2 - Erythematous parietal plaques with mild exfoliation - Spotting mainly on the extremities - Accompanied by intense Row 5: pruritus - Well circumscribed, circular, red plaques with a silvery leap. -Distribution on the elbows, knees, hairy. - All types of psoriasis",
      "start_page": 457,
      "end_page": 457
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: |",
      "start_page": 458,
      "end_page": 458
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: teBlaikthomyus sedophore Specific dose administration may be impaired or may be impaired in the treatment of attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination. Row 2: Mild-moderate: GER 30-89ml/min - Dependent",
      "start_page": 472,
      "end_page": 472
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: OpiateActive, renally excreted metabolitesRemoves by hemodialysisSafe and effective in blood-diluted Row 2:  Row 3: MorphineYesAvoid as much as Row 4: Become Row 5: Hydromorphone(Yes)YesYes, with caution Row 6: OxycodoneYes(Yes)know",
      "start_page": 472,
      "end_page": 472
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Responsive relationshipRow recommendation level 2: p.omorphine on p.ooxycodone1.5:1Strong Row 3: p.omorphine on buprenorphineTTS75:1Patient Row 4: p.omorphine on fentanylTTS100:1Strong",
      "start_page": 474,
      "end_page": 474
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Row 2: Competitors5HT3 is the choice drug for the treatment of acute nausea and vomiting",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Row 2: Risk assessment for symptoms and selection of appropriate antiemetics Row 3: Recommendation for adequate and regular use of antiemetics Row 4: Practical measures: Avoiding exposure to odors, small frequent meals, good oral hygiene, calm Row 5: environment, avoid alcohol Row 6: Treating symptoms initially with an antiemetic drug based on the alleged cause Row 7:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 1)",
      "text": "Row 1: Row 2: Competitors5HT3 is the choice drug for the treatment of acute nautilus",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 1)",
      "text": "Row 1: Row 2: Risk assessment for symptoms and selection of appropriate antiemetics Row 3: Recommendation for adequate and regular use of antiemetics Row 4: Practical measures: Avoiding exposure to smells, small frequent meals, good hygiene in Row 5: environment, avoid alcohol Row 6: Treating symptoms initially with an antiemetic drug on the basis of ecosmose Row 7: Using each other",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 2)",
      "text": "Row 1: Row 2: ja and vomiting",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: toma, calm Row 5: Row 6: one cause Row 7: Row 8: Row 9: Range Row 10: Row 11: the Row 12: Row 13:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Antiemetic drugs Row 2: Row 3: Antagonists 5HT3: ondasetron , granisetron, palonosetron Row 4: Antagonists NK1: aprepitant , fosaprepitant Row 5: Corticosteroids: dexamethasone Row 6: Dopamine receptor antagonists: halomoid proproids,",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 1)",
      "text": "Row 1: Antiemetic drugs Row 2: Row 3: 5HT3 antagonists: ondasetron , granisetron, palonosetron Row 4: NK1 antagonists: aprepitant , fosaprepitant Row 5: Corticosteroids: dexamethasone Row 6: Dopamine receptor antagonists: haloperid,",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: n Row 4: Row 5: Row 6: etiquette -metoclopr",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: ramide",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: e, dom",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6:mperid",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: done",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6:",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading Face>",
      "text": "Row 1: Stimulants laxativesBisacodylWarning use if there is a possibility of Sennaenteric obstruction Row 2: Faecal softenersSodium docusate Row 3: Osmotic laxativesLiquid paraffin Macrogol",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: Row 2: 2. Eric J. Roeland, Kari Bohlke, Vickie E. Baracos, Eduardo Bruera, Egidio del Fabbro, Suzanne Dixon, Marie Row 3: Fallon, JrnHerrstedt, Harold Lau, Mary Platek, Hope S. Rugo, Hester H. Schnipper, Thomas J. Smith.",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1:  Row 2: 14. Loprinzi CL, Kugler jacket JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK,n JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK:",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1:  Row 2: 1. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligiment JA, Row 3: Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology.Lysen GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology.",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: J Clin Oncol. 2014;32(17):1840. Epub 2014 Apr 14 Row 2:  Row 3: 2. Cella D, Davis K, Breitbart W, Curt G, Fatigue Coalition. Cancer-related fatigue: prevalence of proposed Row 4: diagnostic criticism 2001 a United States scandal.",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: Scotland, Healthcare Improvement Scotland 8. Row 2: 3. Lipowski ZJ Delirium (acute Consular states).JAMA. 1987;258(13):1789. Row 3: 4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. AMC.",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is > (from previous page)",
      "text": "Row 1: DiseasesCommercial name of the vaccineSynapismChrosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis osma oscillosis oscillosis oscillosis oscillosis oscillosis os",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tidas (respiratory syncytial virus, RSV) is > (from previous page, column 4)",
      "text": "Row 1: RecommendationChronicsObservations Row 2: Adequate vaccinations for the first time, adequate vaccinations for the first time, adequate vaccinations for the first time, adequate vaccinations for the second year, and adequate vaccinations for the next 65 years.",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is > (from previous page)",
      "text": "Row 1: Hepatia tida B /HBVEngerixIn the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb, let it be in the womb, let it be in the environment, in the womb, in the womb, in the womb, and in the womb, in the womb, in the blood, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the blood, in the womb, in the womb, and in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, and in the womb, in the womb, and in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tidas (respiratory syncytial virus, RSV) is > (from previous page, column 6)",
      "text": "Row 1: In sickness with others rather than sons of danger mind (sexual , professional , environmental suffix, use drug , time for liver disease aunt, Row 2: sugar dia) In sickness with others than sons of danger mind (sexual , professional , environmental suffix , use",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is > (from previous page)",
      "text": "Row 1: Anemylium Varivax                                              Row 2:",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tidas (respiratory syncytial virus, RSV) is > (from previous page, column 5)",
      "text": "Row 1: nos) and have no disease tendinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis Row 2: niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinitis niacinosis niacinitis niacinitis nia nia nia nia nia niacinitis nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia",
      "start_page": 519,
      "end_page": 519
    }
  ]
}